Zylox-Tonbridge Medical Technology Co (HKSE:02190) ROCE % : 4.50% (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Zylox-Tonbridge Medical Technology Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Zylox-Tonbridge Medical Technology Co's annualized ROCE % for the quarter that ended in Jun. 2024 was 4.50%.

Zylox-Tonbridge Medical Technology Co ROCE % Historical Data

The historical data trend for Zylox-Tonbridge Medical Technology Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zylox-Tonbridge Medical Technology Co ROCE % Chart

Zylox-Tonbridge Medical Technology Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

-37.78

-32.44

-11.11

-3.44

-2.49

Zylox-Tonbridge Medical Technology Co Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROCE %	Get a 7-Day Free Trial					-1.56	-5.49	-2.23	-2.77	4.50

Zylox-Tonbridge Medical Technology Co ROCE % Calculation

Zylox-Tonbridge Medical Technology Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-84.749	/	( ( (3633.45 - 169.834)	+	(3692.27 - 347.584) )	/ 2 )
	=	-84.749	/	( (3463.616	+	3344.686)	/ 2 )
	=	-84.749	/	3404.151
	=	-2.49 %

Zylox-Tonbridge Medical Technology Co's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	150.888	/	( ( (3692.27 - 347.584)	+	(3753.362 - 386.054) )	/ 2 )
	=	150.888	/	( ( 3344.686	+	3367.308 )	/ 2 )
	=	150.888	/	3355.997
	=	4.50 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

Zylox-Tonbridge Medical Technology Co (HKSE:02190) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Zylox-Tonbridge Medical Technology Co ROCE % Related Terms

Thank you for viewing the detailed overview of Zylox-Tonbridge Medical Technology Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Zylox-Tonbridge Medical Technology Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Zylox-Tonbridge Medical Technology Co Ltd (HKSE:02190) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

270 Shuyun Road, Cangqian Street, Zylox-Tonbridge Industrial Park, Yuhang District, Zhejiang Province, Hangzhou, CHN

Website

https://www.zyloxtb.com

Zylox-Tonbridge Medical Technology Co Ltd is principally engaged in providing solutions to patients and physicians with a product portfolio covering peripheral-vascular interventional devices and neurovascular interventional devices in China and other countries. The company's main products include Thrombite Clot Retriever Device (Thrombite CRD) and Ultrafree Drug Coated PTA Balloon Catheter (Ultrafree DCB).

Executives

Gan Zhou Ti Tan Gu Quan Tou Zi He Huo Qi Ye You Xian He Huo	2501 Other
Su Zhou Tai Hong Jing Hui Tou Zi Zhong Xin You Xian He Huo	2501 Other
Five Investment Limited	2501 Other
Highlight Medical Limited	2501 Other
Ourea Biotech Hk Limited	2501 Other
Wang Stephen Hui	2201 Interest of corporation controlled by you
Ning Bo Bao Shui Qu Tie Si Yi Gu Quan Tou Zi He Huo Qi Ye You Xian He Huo	2501 Other
Jia Jian Tou Zi You Xian Gong Si	2501 Other
Wea Enterprises ,llc	2401 A concert party to an agreement to buy shares
Hu Zhou Yu Yi Hui Qi Ye Guan Li He Huo Qi Ye You Xian He Huo	2401 A concert party to an agreement to buy shares
Ning Bo Gui Qiao Qi Ye Guan Li He Huo Qi Ye You Xian He Huo	2401 A concert party to an agreement to buy shares
Zhu Hai Gui Chuang Gu Quan Tou Zi Zhong Xin You Xian He Huo	2401 A concert party to an agreement to buy shares
Hang Zhou Fu Jiang Tou Zi He Huo Qi Ye You Xian He Huo	2401 A concert party to an agreement to buy shares
Zhu Hai Tong Qiao Tou Zi Zhong Xin You Xian He Huo	2401 A concert party to an agreement to buy shares
Li Zheng	2501 Other

Zylox-Tonbridge Medical Technology Co Headlines

No Headlines